VTGN - Vistagen Therapeutics Inc

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• VistaGen Therapeutics GAAP EPS of -$8.51 misses by $0.11
• Vistagen regains listing compliance with Nasdaq
• Vistagen posts real world data to highlight hot flashes therapy
• Vistagen announces reverse stock split as part of Nasdaq compliance plan
• Russell 3000 rejig: InMode, Assertio among healthcare additions; Inovio, Bionano among deletions
• Vistagen up 17% after Phase 3 data for anxiety candidate
• VistaGen readies 12M-share secondary offering
• Vistagen secures new U.S. patent for PH80 nasal spray for migraine
• VistaGen slips as mid-stage study for anxiety therapy remains on hold
• VistaGen Therapeutics GAAP EPS of -$0.05 beats by $0.02, revenue of $0.18M misses by $0.13M
• VistaGen acquiring Pherin Pharma acquisition to bolster neuropsychiatric portfolio
• Vistagen surges 30% on FDA fast track status for nasal spray for depression
• Vistagen stock rises ~10% on FDA nod to proceed with trial for depression nasal spray
• VistaGen Therapeutics GAAP EPS of -$0.08
• VistaGen Therapeutics Q2 2023 Earnings Preview
• VistaGen to proceed with phase 3 anxiety nasal spray trial following interim analysis
• VistaGen Therapeutics stock slips 13% after FQ1 revenue fall, bottom line miss
• VistaGen Therapeutics GAAP EPS of -$0.10 misses by $0.02, revenue of $0.31M beats by $0.07M
• VistaGen Therapeutics FQ1 2023 Earnings Preview
• VistaGen downgraded to neutral at Baird on pivotal trial failure